FDA Grants Orphan Drug Designation for the Treatment of Scleroderma
NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ -- BLR Bio, an emerging biotechnology company in Rosalind Franklin University's Helix 51 biomedical incubator , announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma.